Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab

Folkmane, Inese; Bicans, Janis; Amerika, D; Chapenko, Svetlana; Murovska, Modra; Rosentals, R

doi:10.1016/s0041-1345(01)02366-1

Cited by 14 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, we report the longest follow‐up analysis of the effect of IL2R Abs on acute rejection and graft survival after renal transplantation, and compare these agents to no induction and to antilymphocyte antibodies. We find that IL2R Abs reduce acute rejection compared to no induction by 19% at 6 months, consistent with the findings of prior randomized control trials (1–9), meta‐analyses (10,11) and retrospective database analyses (12). We also confirm the limited available data showing that IL2R Abs improve graft survival by 10% compared to no induction (12).…”

Section: Discussionsupporting

confidence: 89%

“…In randomized‐controlled trials of induction in renal transplantation, the IL2R Abs basiliximab and daclizumab decrease acute rejection compared to placebo by 28%–46% within the first year after transplant (1–9). In these trials, the number of patients needed to treat with IL2R Abs to prevent one episode of rejection would be 5–11 patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Anti-IL-2 Receptor Antibodies Compared to no Induction and to Antilymphocyte Antibodies in Renal Transplantation

Patlolla

Zhong

Reed

et al. 2007

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Efficacy of Anti-IL-2 Receptor Antibodies Compared to no Induction and to Antilymphocyte Antibodies in Renal Transplantation

Patlolla

Zhong

Reed

et al. 2007

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…In this study, we report one-year follow up analysis of the effect of IL2-R blockers on acute rejection and graft and patient survival after renal transplantation. IL2-R blockers reduced the rate of early acute rejection episodes compared with no induction (28.6% for IL2-R blockers vs. 22.2% for no induction), consistent with the findings of prior randomized trials ( 8 - 12 , 18 - 20 ), meta-analysis ( 13 , 21 ) and retrospective data base analyses ( 2 , 22 ).…”

Section: Discussionsupporting

confidence: 86%

“…In a randomized controlled trials of IL2-R blockers induction, Basiliximab and Daclizumab decrease acute rejection compared to placebo by 28-46% within the first year after transplant ( 8 - 12 ), but were not associated with improving one year graft survival ( 7 - 14 ). With reference to 2006 NAPRTCS data, 28.6% of patients received Basiliximab and 20.6% received Daclizumab for induction, but it reduced to 21.5% for Basiliximab and 16.3% for Daclizumab in 2010 ( 15 ).…”

Section: Introductionmentioning

confidence: 99%

Effects of Interleukin 2 Receptor Blockers on Patient and Graft Survival in Renal-Transplanted Children

et al. 2014

View full text Add to dashboard Cite

Background:Monoclonal antibodies block interleukin-2 receptors on alloantigen-reactive T-Lymphocytes and induce selective immunosuppression. It is postulated that induction therapy with these agents in pediatric transplantation may decrease acute rejection and improve graft survival with no significant side effect or increase in the incidence of viral infections.Objectives:The aim of this study was to examine the effects of interleukin 2 receptor blockers on patient and graft survival in renal-transplanted children.Patients and Methods:One hundred and eighty six children aged 7-13 years who received renal transplantation in university-affiliated hospital between 2003 and 2012 were enrolled in the study. All patients received prednisolone, cyclosporine and mycophenolate mofetil or azathioprine as basic immunosuppressive therapy. Patients were divided into two groups according to receiving induction therapy with IL2-receptor blockers. We investigated for acute rejection episodes, Cytomegalovirus (CMV) and BK virus infection and one and three year’s survival of the patients and the graftsResults:From 186 renal-transplanted children included in this study, 36 patients were in treated group (group 1) and 150 patients in control group (group 2). The mean age of the patients was 10.4 ± 2 years and 55.6% were males. In first six months of transplantation, eight patients in group one had one episode of acute rejection and no one had two episodes. Early acute rejection rate was 8.36 (22%). In the control group, 37 patients had one episode and three patients had two episodes of acute rejection (rejection rate 28.6%). Therefore, early acute rejection rates were lower in group one. Late acute rejection rates did not show any difference in group 1 and group 2 (27.7% vs. 27.3% respectively). There was lower prevalence of steroid-resistance rejection in group 1 patients (5.5%) compared with 6.6% in group 2, but it did not reach statistical significance. None of the patients in IL2-R blocker group died at one year follow-up (patient survival 100%). However, in control group, four (2.6%) patients died toward the end of first year (patient survival 97.4%). When patients in group 1 and group 2 were age and sex matched with equal number the difference was significant (P < 0.05).Conclusions:Induction therapy with IL2-R blockers reduced the rate of early acute rejection, but had no effect on late acute rejections. Patient and graft survival were better in treated group, but did not reach statistical significance. A longer period of follow-up may be required to discern a clear advantage for induction therapy with these agents.

show abstract

“…[57][58][59] All four trials used a triple therapy combination of ciclosporin + azathioprine + steroids in both treatment arms.…”

Section: Adult Randomised Controlled Trialsmentioning

confidence: 99%

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children

Yao¹,

Albon²,

Adi³

et al. 2006

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab

Cited by 14 publications

References 3 publications

Efficacy of Anti-IL-2 Receptor Antibodies Compared to no Induction and to Antilymphocyte Antibodies in Renal Transplantation

Efficacy of Anti-IL-2 Receptor Antibodies Compared to no Induction and to Antilymphocyte Antibodies in Renal Transplantation

Effects of Interleukin 2 Receptor Blockers on Patient and Graft Survival in Renal-Transplanted Children

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children

Contact Info

Product

Resources

About